Rexgenero extends European reach with expanded manufacturing

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/royaltystockphoto)
(Image: Getty/royaltystockphoto)

Related tags: Europe, Germany, Bone marrow, Clinical trials, drug candidate, Blood

Partnership with German Red Cross will see Rexgenero’s lead drug candidate reaching broader patient base in clinical trials.

Rexgenero has expanded manufacturing of its lead candidate with its previously announced partnership with the German Red Cross blood donor service.

After signing an agreement with the blood donor service earlier this year, the regenerative medicine company, focused on developing advanced cell-based therapies for critical limb ischaemia (CLI), has bolstered its manufacturing capabilities for its lead candidate, REX-001.

The lead candidate is an autologous cell-based therapy that is manufactured using a patient’s own bone marrow. According to Rexgenero, manufacture of the drug candidate is time sensitive and administration of the ‘fresh product’ must be within 48 hours.

The drug candidate is already manufactured at the company’s facility in Seville, Spain, and has been used at clinical trial sites in Spain and Portugal.

However, with the additional manufacturing partnership, the German Red Cross blood donor service will manufacture REX-001 for the use at trial sites in Germany, Poland, Czech Republic, Hungary, the Netherlands, the UK, and Austria.

After the transfer of manufacturing technology, a sufficient supply of the drug candidate is ensured for patients enrolled in Phase III trials of REX-001 for the treatment of CLI in patients with diabetes.

Halvard Bönig, professor at the Institute for Transfusion Medicine and Immunohematology at Goethe-University, will oversee production of REX-001 at the German Red Cross blood service in Frankfurt, Germany and Main, Germany.

 

Related news

Show more

Related products

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars